A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's ...

Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...

GLP-1 receptor agonists like semaglutide and the dual GIP/GLP-1 agonist tirzepatide mimic naturally occurring hormones that regulate blood sugar, appetite, and digestion. GLP-1 (glucagon-like ...

In this week’s InnovationRx newsletter, we look at longevity drugs for dogs, programmable mRNA for fighting cancer, AI models ...

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

Broadcom, Philip Morris, and Novo Nordisk face contrasting outlooks as AI growth, smoke-free expansion, and obesity drug ...

GLP-1s, injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity.

Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.

Ozempic a brand name for semaglutide works by mimicking a natural hormone that helps your body regulate blood sugar reduce ...

A study published in JAMA Network, by the Case Western Reserve University examined about 15,11,637 eligible participants with ...